HIV Primary Care


Published on

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • These charts illustrate the risk behaviors reported by persons newly diagnosed with HIV or AIDS in recent years (2001 through 2004) in the 33 states with name-based HIV/AIDS reporting. They represent new diagnoses – not necessarily new or recent infections. Approximately 29% of these new cases were among women. Injection drug use accounts for approximately 20% of cases among both men and women. The route of infection among the majority (61%) of men was male-to-male sexual contact. The majority (76%) of females with HIV/AIDS diagnosed were exposed through high-risk heterosexual contact.
  • 1. Bell DM. Am J Med 1997;102(suppl 5B):9--15. 2. Ippolito G et al. Arch Int Med 1993;153:1451--8. 3. Am J Epidemiology 1999;150:306-11. 4. Am J Epidemiology 1999;150:306-11. 5. MMWR 47;RR-17, 1998. 6. NEJM 336(15):1072-8. (rates in Europe & U.S.) 7. Am J Epidemiology 1999;150:306-11. 8. Rothenberg RB et al. AIDS 1998;12:2095-2105. 9. MMWR 47;RR-17, 1998. 10. ACTG 076
  • The primary goal of the new initiative – to reduce HIV transmission – is not new. AHP emphasizes the use of proven public health approaches to reduce incidence and the spread of disease. The initiative consists of four priority strategies: Make voluntary testing a routine part of medical care. Implement new models for diagnosing HIV infections outside medical settings. Prevent new infections by working with persons diagnosed with HIV. Further decrease perinatal HIV transmission.
  • The decision to begin therapy for the asymptomatic patient is complex and must be made in the setting of careful patient counseling and education. Considerations of initiating antiretroviral therapy should be primarily based on the prognosis of disease-free survival as determined by baseline CD4 + T cell count [27-29] ( Figure A ; and Table 3a, 3b ) . Also important are baseline viral load [27-29] , readiness of the patient to begin therapy; and assessment of potential benefits and risks of initiating therapy for asymptomatic persons, including short-and long-term adverse drug effects; the likelihood, after counseling and education, of adherence to the prescribed treatment regimen. Recommendations vary according to the CD4 count and viral load of the patient, as follows. <200 CD4 + T cell count, with AIDS-defining illness, or symptomatic. Randomized clinical trials provide strong evidence of improved survival and reduced disease progression by treating symptomatic patients and patients with <200 CD4 + T cells/mm 3 [30-33]. Observational cohorts indicate a strong relationship between lower CD4 + T cell counts and higher plasma HIV RNA levels in terms of risk for progression to AIDS for untreated persons and antiretroviral naïve patients beginning treatment. These data provide strong support for the conclusion that therapy should be initiated in patients with CD4 + T cell count <200 cells/mm 3 ( Figures A and Table 3a ) (AI) [27, 28]. 200-350 CD4 + T cell count, patient asymptomatic. The optimal time to initiate antiretroviral therapy among asymptomatic patients with CD4 + T cell counts >200 cells/mm 3 is unknown. For these patients, the strength of the recommendation for therapy must balance other considerations, such as patient readiness for treatment and potential drug toxicities. After considering available data in terms of the relative risk for progression to AIDS at certain CD4 + T cell counts and viral loads, and the potential risks and benefits associated with initiating therapy, most specialists in this area believe that the evidence supports initiating therapy in asymptomatic HIV-infected persons with a CD4 + T cell count of 200-350 cells/mm 3 (BII) . There is a paucity of data from randomized, controlled trials concerning clinical endpoints (e.g., the development of AIDS-defining illnesses or death) for asymptomatic persons with >200 CD4 + T cells/mm 3 to guide decisions on when to initiate therapy. Observational data from cohorts of HIV-infected persons provide some guidance to assist in risk assessment for disease progression. … . While there are clear strengths to these observational data, there are also important limitations. Uncontrolled confounding factors could impact estimates in both studies. Furthermore, neither study provides direct evidence on the optimum CD4 + T cell count to begin therapy. Such data will have to come from studies that follow patients who start therapy at different CD4 + T-cell counts above 200 cells/mm 3 and compare them with a similar group of patients (e.g., with similar CD4 + T cell count and HIV RNA level) who defer treatment. To completely balance the benefits and risks of therapy, follow-up will have to examine progression to AIDS, major toxicities, and death. >350 CD4 + T cell count, patient asymptomatic. There is little evidence on the benefit of initiating therapy in asymptomatic patients with CD4 + T cell count > 350 cells/mm 3 . Most clinicians would defer therapy. • The deferred treatment approach is based on the recognition that robust immune reconstitution still occurs in the majority of patients who initiate treatment while CD4 + T cell counts are in the 200–350 cells/mm 3 range. Also, toxicity risks and adherence challenges generally outweigh the benefits of initiating therapy at CD4 + T cell counts >350 cells/mm 3 . In the deferred treatment approach, increased levels of plasma HIV RNA (i.e., >100,000 copies/mL) are an indication for monitoring of CD4 + T cell counts and plasma HIV RNA levels at least every three months, but not necessarily for initiation of therapy. For patients with HIV RNA <100,000 copies/mL, therapy should be deferred (DII) . • In the early treatment approach, asymptomatic patients with CD4 + T cell counts >350 cells/mm 3 and levels of plasma HIV RNA >100,000 copies/mL would be treated because of the risk for immunologic deterioration and disease progression (CII) . An estimate of the short term risk of AIDS progression may be useful in guiding clinicians and patients as they weigh the risks and benefits of initiating versus deferring therapy in this CD4 cell range. As cited above, Table 3b provides an analysis of data from the CASCADE Collaboration, demonstrating the risk of AIDS progression within 6 months for different strata of CD4 + T cell count, viral load, and age. As seen in Table 3b , a 55 year old with a CD4 + T cell count of 350 and a HIV viral load of 300,000 copies/ml has a 5% chance of progression in 6 months, compared with a 1.2% chance for a similar patient with a viral load of 3000 copies/mL.
  • Three NNRTIs (namely, delavirdine, efavirenz, and nevirapine) are currently marketed for use. NNRTI-based regimens are commonly prescribed as initial therapy for treatment-naïve patients. In general, these regimens have the advantage of lower pill burden as compared to most of the PI-based regimens. Use of NNRTI-based regimens as initial therapy can preserve the PIs for later use, reducing or delaying patient exposure to some of the adverse effects more commonly associated with PIs. The major disadvantage of currently available NNRTIs is their low genetic barrier for development of resistance. These agents only require a single mutation to confer resistance, and cross resistance often develops across the entire class. As a result, patients who fail this initial regimen may lose the utility of other NNRTIs and/or may transmit NNRTI-resistant virus to others. Based on clinical trial results and safety data, the Panel recommends the use of efavirenz as the preferred NNRTI as part of initial antiretroviral therapy (AII) . The exception is during pregnancy (especially during the first trimester) or in women who are planning to conceive or women who are not using effective and consistent contraception. Nevirapine may be used as an alternative to efavirenz as the initial NNRTI-based regimen. (BII) Close monitoring of liver enzymes and skin rash should be undertaken during the first 18 weeks of nevirapine therapy, particularly, in female patients with CD4 + T-cell count >250 cells/mm 3 prior to therapy initiation. Among these three agents, delavirdine appears to have the least potent antiviral activity. As such, it is not recommended as part of an initial regimen. (DII) PI-based regimens (1or 2 PIs + 2 NRTIs) revolutionized the treatment of HIV infection, leading to sustained viral suppression, improved immunologic function, and prolonged patient survival. Since their inception in the mid-1990s, much has been learned about their efficacy as well as some short term and long term adverse effects. To date, eight PIs have been approved for use in the United States. Each agent has its own unique characteristics based on its clinical efficacy, adverse effect profile, and pharmacokinetic properties. The characteristics, advantages, and disadvantages of each PI can be found in Tables 6 & 12 . In selecting a PI-based regimen for a treatment-naïve patient, factors such as dosing frequency, food and fluid requirements, pill burden, drug interaction potential, baseline hepatic function, and toxicity profile should be taken into consideration. A number of metabolic abnormalities, including dyslipidemia, fat maldistribution, and insulin resistance, have been associated with PI use. The eight PIs differ in their propensity to cause these metabolic complications. At this time, the extent to which these complications may result in adverse long term consequences, such as increased cardiac events in chronically-infected patients, is unknown. The potent inhibitory effect of ritonavir on the cytochrome P450 3A4 isoenzyme has allowed the addition of low dose ritonavir to other PIs as a “pharmacokinetic booster” to increase drug exposure and prolong serum half-lives of the active PIs. This allows for reduced dosing frequency and pill burden, and in the case of indinavir, the addition of low dose ritonavir eliminates the need for food restrictions. All these advantages may improve overall adherence to the regimen. The increased trough concentration (C min ) may improve the antiretroviral activity of the active PIs, which is most beneficial in cases where the patient harbors HIV-1 strains with reduced susceptibility to the PI [61-63]. The major drawbacks associated with this strategy are the potential for increased risk of hyperlipidemia and a greater potential of drug-drug interactions from the addition of ritonavir. The Panel considers lopinavir/ritonavir as the preferred PI for the treatment-naive patient (AII) . Discussed below, this recommendation is based on clinical trial data for virologic potency, barrier for virologic resistance, and patient tolerance. However, there are limited data on the comparative efficacy of lopinavir/ritonavir with other ritonavir-boosted regimens. Alternative PIs are listed in Table 5 and discussed below in greater detail and may include atazanavir (BII) , fosamprenavir (BII) , or nelfinavir (CII) as sole PI, or ritonavir-boosted fosamprenavir (BII) , indinavir (BII) , or saquinavir (BII) .
  • HIV Primary Care

    1. 1. Primary Care Approach To The HIV Patient Tahseen J. Siddiqui, M.D., M.R.C.P Medical Director, Infectious Disease/HIV/STD Prevention & Care Program Jackson Park Hospital & Medical Center Chicago
    2. 2. HISTORY& EPIDEMIOLOGY OF HIV <ul><li>HIV-? a descendant of a Simian Immunodeficiency Virus (SIV), transferred iatrogenically (polio/small pox vacc) </li></ul><ul><li>1981- First case in the USA (KS > PCP) </li></ul><ul><li>Globally, ~40 million adults and 2.2 million children living with HIV </li></ul><ul><li>During 2004, some 4.9 million people became infected with the HIV and 3.1 million died from AIDS </li></ul><ul><li>In the US ~ 421,873 persons living with HIV;~ 40,000 become infected each year, and 16,316 died of AIDS (2005); ~25% unaware of their HIV </li></ul><ul><li>Reemergence of TB (MDR-late 1980s New York city), Syphilis ((2003) </li></ul>Dr. Conant and Dr. Volberg discussing Kaposi's Sarcoma 1981
    3. 3. EPIDEMIOLOGY Global Distribution of HIV Officially, there are 1,710 people living with HIV in Pakistan today, a nation of over 140 million. However, given the taboo nature of the subject, few infected people disclose their status. Some experts estimate the true number of HIV-positive people to be closer to 80,000. Around 2.5 million people in India are living with HIV.
    4. 4. Increase In HIV Cases
    5. 5. USA STATES Geographical Distribution of HIV/AIDS (2003) 72% of all AIDS cases to date have been reported from just ten states New York - /66,311 California - /55,612 Florida 32,196 / 42,861 Texas 20,820 /29,958 New Jersey 15,192/ 16,969 Illinois - /14,241 Georgia - /13,963 Maryland - /12,830 North Carolina 11,118 /6,519 Total 172,714 /393,375
    6. 6. Racial & Gender Differences
    7. 7. HIV/AIDS Diagnoses among Adults and Adolescents, by Transmission Category — 33 States, 2001–2004 MSM 61% IDU 16% Heterosexual 17% MSM/IDU 5% Other 1% Males (n ≈ 112,000) Females (n ≈ 45,000) Heterosexual 76% IDU 21% Other 3% MMWR, Nov 18, 2005
    8. 8. Changing Faces of HIV/AIDS No Longer A Disease of Gay Men And Drug Abusers
    9. 9. Modes Of Transmission A GUIDE TO THE CLINICAL CARE OF WOMEN WITH HIV Epidemiology and Natural History of HIV Infection in Women
    10. 10. HIV TRANSMISSION (Average, per episode, involving HIV-infected source patient ) HCV 3% and HBV 30% risk by needle stick injury 24% Vertical (no prophylaxis) 10 0.67% IDU needle sharing 9 4 case reports Female-female orogenital 8 0.06% Receptive oral (male) 7 0.03 – 0.14% Insertive vaginal intercourse 6 0.1 – 0.2% Receptive vaginal intercourse 5 0.06% Insertive anal intercourse 4 1% Receptive anal intercourse 3 0.09% Mucocutaneous (blood) 2 0.3% Percutaneous (blood) 1
    11. 11. You CANNOT get HIV from: <ul><li>a toilet seat </li></ul><ul><li>being coughed or sneezed on </li></ul><ul><li>sharing eating utensils </li></ul><ul><li>living with someone who is HIV positive </li></ul><ul><li>sharing a bathroom </li></ul><ul><li>tears, saliva, or sweat </li></ul><ul><li>casual contact </li></ul><ul><li>Being exposed to vomitus, urine or stool </li></ul>In High Risk exposure, prophylaxis (2-3 drugs) is recommended. Must start <72 h and continue for 4 weeks
    12. 12. FACTORS FACILITATING TRANSMISSION & PROGRESSION OF HIV <ul><li>INFECTIOUSNESS OF THE HOST </li></ul><ul><li>VL>1000,000 </li></ul><ul><li>SUSCEPTIBILITY OF THE RECIPIENT </li></ul><ul><li>1 ) Physical/Physiological Factors </li></ul><ul><li>Inflammation or disruption of the genital or rectal mucosa </li></ul><ul><li>(sex during menstruation , traumatic sexual intercourse , ulcerative and non-ulcerative STDs and changes in the vaginal flora, as characterized by bacterial vaginosis) and lack of circumcision in heterosexual men,, may facilitate acquisition of HIV. </li></ul><ul><li>2) Genetic or Immunologic Factors </li></ul><ul><li>CCR5 (coreceptor with cd4) homozygotes are resistant to HIV infection and to HLA Class 1 heterozygotes have slow progression . </li></ul>
    13. 13. HIV Cycle
    15. 15. HIV NATURAL HISTORY Based On CD4 Cell Count & Viral Load
    16. 16. Primary HIV Infection (4-12 weeks post infx) Seroconversion Illness, Acute Retroviral Syndrome (‘Bad Flu’)
    17. 17. Opportunistic Infections
    18. 18. PRIMARY AIDS Defining Illnesses <ul><ul><li>Candidiasis (Thush, esophageal, trachea, or lungs) </li></ul></ul><ul><ul><li>Cervical cancer (invasive) </li></ul></ul><ul><ul><li>Coccidioidomycosis , Cryptococcosis , Histoplasmosis (disseminated or extrapulmonary) </li></ul></ul><ul><ul><li>Cryptosporidiosis , Isosporiasis (> 1 month ) </li></ul></ul><ul><ul><li>Cytomegalovirus disease (CMV) (other than liver , spleen or lymph nodes ) </li></ul></ul><ul><ul><li>Encephalopathy (HIV-related) </li></ul></ul><ul><ul><li>Herpes simplex (>1 month or in an area other than the skin such as esophagus or lungs) </li></ul></ul><ul><ul><li>Kaposi's sarcoma (KS) </li></ul></ul><ul><ul><li>Lymphoma ( Burkitt's , immunoblastic or primary brain ) </li></ul></ul><ul><ul><li>Mycobacterium avium complex (MAC) </li></ul></ul><ul><ul><li>Pneumocystis jiroveci pneumonia (PCP) </li></ul></ul><ul><ul><li>Pneumonia (recurrent) </li></ul></ul><ul><ul><li>Progressive multifocal leukoencephalopathy (PML) </li></ul></ul><ul><ul><li>Salmonella septicemia (recurrent) </li></ul></ul><ul><ul><li>Toxoplasmosis of the brain </li></ul></ul><ul><ul><li>Tuberculosis </li></ul></ul><ul><ul><li>Wasting syndrome </li></ul></ul><ul><li>Sources: Information prov </li></ul>
    19. 19. HIV Presents To Dermatologist Kaposi's sarcoma SEROCONVERSION ILLNESS Herpes Simplex Herpes Zoster ( Shingles ) Molluscum Contagiosum Kaposi's sarcoma
    20. 20. HIV Presents To Dermatologist Warts Oral 'Hairy' Leukoplakia Oral Candidiasis 'Thrush' onchomycosis Bacillary angiomatosis psoriasis Seborrheic dermatitis HSV Crypto disseminated
    21. 21. HIV Presents To Pulmonologist PCP Military TB Kaposi's sarcoma
    22. 22. HIV Presents To Gastroenterologist Candida esophagitis (HSV) esophagitis CMV Proctitis Primary gastric lymphoma Kaposi's sarcoma – GI lesions
    23. 23. HIV Presents To Nephrologist <ul><li>HIV-Associated Nephropathy HIVAN </li></ul><ul><li>Nephrotic syndrome </li></ul><ul><li>(1) proteinuria, (2) azotemia, (3) normal-to-large kidneys on ultrasonography images, (4) normal pressure, and (5) focal segmental glomerulosclerosis (FSGS) on renal biopsy findings. </li></ul><ul><li>Rapid progression to renal failure and end-stage renal disease (ESRD) </li></ul><ul><li>Male-to-female ratio of 10:1. </li></ul><ul><li>Mean age of persons is 33 years. </li></ul><ul><li>Third leading cause of ESRD among black persons aged 20-64 years. </li></ul><ul><li>50% are intravenous addicts </li></ul><ul><li>CD4 count in these patients is usually depressed below 200 cells/  L, but HIVAN has been reported in patients with higher CD4 counts </li></ul><ul><li>Tx: HAART, ACE Inh, Steroids, cyclosporine, Dialysis, Transplant </li></ul>Collapsing form of focal segmental glomerulosclerosis
    24. 24. HIV Presents To Neurologist <ul><li>Peripheral neuropathy </li></ul><ul><li>the most frequent neurologic disorder associated with HIV(occurs in over 30% of individuals with AIDS. </li></ul><ul><li>predominantly sensory neuropathy (PSN) or distal symmetric polyneuropathy (DSPN), and medication-induced toxic neuropathy.(antiretroviral agents ddI and d4T ) </li></ul>
    25. 25. HIV Presents To Neurologist <ul><li>HIV-Associated Myopathy / AZT Myopathy </li></ul><ul><li>Pain and weakness thighs and shoulders </li></ul><ul><li>(CPK/EMG/NCVs) </li></ul><ul><li>Polyradiculitis : Rapidly evolving weakness and numbness in legs (both proximally and distally), with bowel/bladder incontinence. EMG/NCV shows multilevel nerve root involvement. Spinal fluid helpful in determining etiology (cytomegalovirus or herpes simplex virus infections, lymphomatous infiltration). </li></ul>PML AIDS Dementia Primary CNS Lymphoma CNS Toxo
    26. 26. Metabolic Abnormalities Changes in glucose and lipids occur early after the initiation of therapy and before the development of body shape changes.
    27. 27. HIV- HAART Vs HEART
    28. 28. Metabolic Abnormalities HIV Infection Itself Increase the Risk of Diabetes relative risk of 3.32
    29. 29. Management <ul><li>Standard guidelines (diet,exercise, weight loss) but be realistic! </li></ul><ul><li>Treatment modifications (Avoid PI -based regimens in DM/Dyslipidemia) </li></ul><ul><li>Insulin-sensitizing agents ( metformin (lactic acid?) & glitazones (liver dis?) </li></ul><ul><li>S tatins: pravastatin preferred, atorvastatin with caution and Simvastatin/lovastatin are contraindicated because of drug interactions with PIs . </li></ul><ul><li>Fibric acid analogues (gemfibrozil/fenofibrate) preferred initial therapy for TG > 500 mg/dl . </li></ul>
    30. 30. HIV Lipodystrophy ‘Fat Redistribution Syndrome’ <ul><li>Similar to a Cushingoid patint </li></ul><ul><li>Overall incidence of lipodystrophy 17% </li></ul><ul><li>Median time on HAART ~18 months, ( NRTI +/- PI) </li></ul>
    31. 31. Management of Lipodystrophy <ul><li>No proven therapy </li></ul><ul><li>Modifications of the treatment regimen may halt progress </li></ul><ul><li>Metformin , preferred in HIV patients with hyperglycemia/insulin resistance and dyslipidemia/lipodystrophy. </li></ul><ul><li>Glitazones/growth hormone is currently under investigation </li></ul><ul><li>Testosterone replacement in hypogonadal HIV-1 infected men with central obesity decreases visceral fat and improves insulin sensitivity. </li></ul><ul><li>Cosmetic Surgery: Facial reconstruction, Liposuction / lipectom </li></ul><ul><li>‘ Sculptra’ Polylactic acid injections </li></ul>
    32. 32. Metabolic Bone Disease <ul><li>Osteonecrosis: </li></ul><ul><li>Involving femoral/humeral heads, femoral condyles, proximal tibia and small bones in hand/wrist, can be caused by HIV/HAART </li></ul><ul><li>Osteopenia & Osteoporosis: </li></ul><ul><li>Occurs in HIV seropositive patients with low CD4+ cells. Rates of osteopenia (22%-50%) and osteoporosis (3%-21%) in PI-based HAART </li></ul>
    33. 33. Advancing HIV Prevention: New Strategies <ul><li>CDC HIV Testing Services for Inpatients and Outpatients in Acute-Care Hospital Settings, recommended routin e HIV screening of all adults, adolescents, and pregnant women in health care settings in the United States. </li></ul><ul><ul><li>Persons at high risk for HIV infection should be screened for HIV at least annually . </li></ul></ul><ul><ul><li>Separate written consent for HIV testing should not be required; general consent for medical care should be considered sufficient to encompass consent for HIV testing. </li></ul></ul><ul><ul><li>Prevention counseling should not be required with HIV diagnostic testing </li></ul></ul><ul><ul><li>HIV Vaccines …. In clinical trials </li></ul></ul><ul><ul><li>Circumcision … reduces HIV transmission by ~60% </li></ul></ul><ul><ul><li>Save sex (condoms) </li></ul></ul><ul><ul><li>STDs … prompt treatment and prevention </li></ul></ul><ul><ul><li>HCW …avoid potential exposures/PEP </li></ul></ul><ul><ul><li>HIV is reportable to the Health Department </li></ul></ul>September 22, 2006
    34. 34. Rapid Diagnosis Four FDA-approved Rapid HIV Tests Results are available in 10-20 min 99.7 (99.0 – 100) 99.8 (99.3 – 100) 100 (99.5 – 100) 100 (99.5 – 100) Uni-Gold Recombigen - whole blood - serum/plasma 100 (99.7-100) 99.8 (99.6 – 99.9) 99.9 (99.6 – 99.9) 99.6 (98.5 - 99.9) 99.3 (98.4 - 99.7) 99.6 (98.5 - 99.9) OraQuick Advance - whole blood - oral fluid - plasma Specificity (95% C.I.) Sensitivity (95% C.I.) 99.9 (99.8 – 100) 100 (99.9 – 100) 100 (99.7 – 100) Multispot - serum/plasma - HIV-2 99.1 (98.8 – 99.4) 98.6 (98.4 – 98.8) 99.8 (99.2 – 100) 99.8 (99.0 – 100) Reveal G2 - serum - plasma Specificity (95% C.I.) Sensitivity (95% C.I.)
    35. 35. HIV- Diagnostic Tests <ul><li>Confirmatory test essential ( ELISA ) </li></ul><ul><li>For Western blot : </li></ul><ul><ul><li>Venipuncture for whole blood </li></ul></ul><ul><ul><li>Oral fluid specimen </li></ul></ul><ul><li>Follow-up testing of persons with negative or indeterminate Western blot results after 4 weeks </li></ul>Microplate ELISA: coloured wells indicate reactivity Interpretation of Western blot results for HIV antibody
    36. 36. Treatment With HAART (Highly Active Antiretroviral Therapy) *The pre-HAART era (1994-1995) *Early-HAART (1996-1997) *Late-HAART (1998 onwards) Incidence of AIDS was about 50% lower in late-HAART when compared with early-HAART. The incidence of death also decreased significantly Median survival on HAART is now ~ 25 years
    37. 37. ‘ COSTS’ Of HAART *Price Tag *Side Effects *Resistance Globally, more than 90 percent of HIV-positive patients do not have access to HAART
    38. 38. When to Start HAART Chronic Infection Treatment should be offered, with consideration of pros and cons Any value >200 cells/µL but <350 cells/µL Asymptomatic Treat Any value <200 cells/µL Asymptomatic, AIDS Treat Any value Any value Symptomatic (AIDS, severe symptoms) Recommendation Plasma HIV RNA CD4 + T Cell Count Clinical Category
    39. 39. When to Start HAART Chronic Infection Defer therapy <100,000 copies/mL CD4 + T cells >350 cells/µL Asymptomatic Most clinicians recommend deferring therapy; some will treat >100,000 copies/mL >350 cells/µL Asymptomatic Recommendation Plasma HIV RNA CD4 + T Cell Count Clinical Category
    40. 40. Pre-Treatment Evaluation <ul><li>Establish readiness to start therapy (physical/psych/drug rehab) </li></ul><ul><li>Ensure Adherence & compliance </li></ul><ul><li>Provide education on medication dosing/transmission </li></ul><ul><li>Anticipate and treat side effects </li></ul><ul><li>Social support / Focus groups </li></ul><ul><li>Simplify regimens, dosing, and food requirements </li></ul><ul><li>Comprehensive care .Utilize team approach with nurses, pharmacists, and peer counselors </li></ul><ul><li>Provide confidentiality and respect </li></ul>
    41. 41. BASELINE EVALUATION Pap smear/Anal Pap/STD screening Vaccination; (annual Influenza/ Pneumovax 3-5 y/ HBV series/ HPV (revaccinate once CD4>200) In addition: • Resistance testing (Genotype/Phenotype) in chronically infected patients prior to initiating antiretroviral therapy • Chest x-ray if clinically indicated. G6PD (in selected patients) PPD (annually) Serologies : RPR, toxoplasma IgG, hepatitis A, hepatitis B, hepatitis C CMV, varicella-zoster virus (if no history of chickenpox or shingles), Lipid profile : total cholesterol, HDL, LDL, triglycerides CBC/Diff CMP: including liver and renal function CD4 count/Viral load (2-8 w after initiating therapy then after every 3-4 months) Confirm HIV (ELISA and Western blot)
    42. 42. Initial Treatment: Preferred Regimens <ul><li>* Avoid in pregnant women and women with high pregnancy potential. </li></ul>NNRTI-Based PI-Based pills/day 2-5 <ul><li>Efavirenz* (Sustiva) plus </li></ul><ul><li>+ (lamivudine or emtricitabine) </li></ul><ul><li>+ (zidovudine or tenofovir) </li></ul><ul><li>(Combivir/Truvada) </li></ul>8-10 <ul><li>Lopinavir/ritonavir (Kaletra) plus </li></ul><ul><li>+ (lamivudine or emtricitabine) </li></ul><ul><li>+ zidovudine </li></ul>
    43. 43. HIV And Pregnancy <ul><li>Without HAART during pregnancy, mother-to-child transmission ~25% (Highest during the intrapartum period) </li></ul><ul><li>Rapid Testing at labor/delivery to late-presenting women </li></ul><ul><li>Prophylaxis should be initiated as soon as possible after a positive rapid HIV test </li></ul><ul><li>Cesarean Section ( VL > 1000 copies/mL) </li></ul><ul><li>Women with HIV should not breastfeed </li></ul>
    44. 44. 3-part ZDV Regimen <ul><ul><li>Antepartum 100 mg ZDV po 5x day, started at 14-34 weeks gestation </li></ul></ul><ul><ul><li>Intrapartum During labor, 1-hour initial dose 2 mg/kg IV followed by continuous infusion of 1 mg/kg/hr until delivery </li></ul></ul><ul><ul><li>Postpartum/infant regimen 2 mg/kg po q 6 hr for 6 weeks, start 8-12 hours after birth </li></ul></ul><ul><ul><li>Risk reduction from 22.6% to 7.6%) </li></ul></ul><ul><li>Today, risk of perinatal transmission can be <2% with </li></ul><ul><ul><li>effective antiretroviral therapy (HAART) </li></ul></ul><ul><ul><li>elective cesarean section (C/S) as appropriate </li></ul></ul><ul><ul><li>formula feeding </li></ul></ul>
    45. 45. Thanks